Therefore, the combined treatment of HTR1A agonists with demethylation drugs such as 5‐aza‐2’‐deoxycytidine may significantly improve the expression of HTR1A and the survival of patients, which might provide a new approach for the treatment of breast cancer patients. Here, HTR1A is linked to breast carcinoma.